3. Agenda - Not To Be Given to Delegates

Thursday 14th February 2019

19:00	PLENARY: For a better understanding of the physiology of hormonal performance enhancement
19:30	Dinner
20:30	DINNER TALK: The history of acromegaly

08:30 Welcome & introduction 08:40 Welcome from host country SESSION1 Second PLENARY: IGFBP activities that are independent of IGF-1 binding 09:25 COUNTRY PERSPECTIVE: Israel 09:40 SYMPOSIUM: Personalised medicine • Who needs surgery first? • Who still needs radiotherapy? 10:40 Coffee break SESSION 2 Image: Strate in the independent of IGF-1 binding 11:10 DEBATE: Personalised medicine in patients with acromegaly requires receptor analysis on the tumour tissue Yes No 12:00 Breakout 1 13:00 Lunch 14:00 Breakout results SESSION 3 Image: Strate in the str
SESSION 1 V 08:50 PLENARY: IGFBP activities that are independent of IGF-I binding 09:25 COUNTRY PERSPECTIVE: Israel 09:40 SYMPOSIUM: Personalised medicine • Who needs surgery first? • Who still needs radiotherapy? • Who still needs radiotherapy? 10:40 Coffee break SESSION 2 Image: State
ORESO PLENARY: IGFBP activities that are independent of IGF-1 binding 09:25 COUNTRY PERSPECTIVE: Israel 09:40 SYMPOSIUM: Personalised medicine · Who needs surgery first? · Who needs radiotherapy? · Who still needs radiotherapy? 10:40 Coffee break SESSION 2 Image: I
O9:25 COUNTRY PERSPECTIVE: Israel 09:40 SYMPOSIUM: Personalised medicine · Who needs surgery first? · Who needs primary medical therapy? · Who still needs radiotherapy? 10:40 Coffee break SESSION 2 Intervention of the personalised medicine in patients with acromegaly requires receptor analysis on the tumour tissue Yes No 11:10 DEBATE: Personalised medicine in patients with acromegaly requires receptor analysis on the tumour tissue Yes No 12:00 Breakout 1 13:00 Lunch 14:00 Breakout results SESSION 3 Intervention of the second
09:40 SYMPO SIUM: Personalised medicine · Who needs surgery first? · Who needs primary medical therapy? 10:40 Coffee break SESSION 2 Interds radiotherapy? 11:10 DEBATE: Personalised medicine in patients with acromegaly requires receptor analysis on the tumour tissue Yes No 12:00 Breakout 1 13:00 Lunch 14:00 Breakout results SESSION 3 Interdes results 14:20 COUNTRY PERSPECTIVE: USA 14:35 SYMPOSIUM:
Who needs surgery first? Who needs primary medical therapy? Who needs primary medical therapy? Who still needs radiotherapy? 10:40 Coffee break SESSION 2 Item and the streak of the streak
SESSION 2 11:10 DEBATE: Personalised medicine in patients with acromegaly requires receptor analysis on the tumour tissue Yes No 12:00 Breakout 1 13:00 Lunch 14:00 Breakout results SESSION 3 COUNTRY PERSPECTIVE: USA 14:35 SYMPOSIUM:
DEBATE: Personalised medicine in patients with acromegaly requires receptor analysis on the tumour tissue Yes No 12:00 Breakout 1 13:00 Lunch 14:00 Breakout results SESSION 3
Yes No 12:00 Breakout 1 13:00 Lunch 14:00 Breakout results SESSION 3 COUNTRY PERSPECTIVE: USA 14:35 SYMPOSIUM:
13:00 Lunch 14:00 Breakout results SESSION 3
14:00 Breakout results SESSION 3 14:20 COUNTRY PERSPECTIVE: USA 14:35 SYMPOSIUM:
SESSION 3 COUNTRY PERSPECTIVE: USA 14:35 SYMPOSIUM:
14:20 COUNTRY PERSPECTIVE: USA 14:35 SYMPOSIUM:
14:35 SYMPOSIUM:
The new WHO classification criteria for pituitary tumours Criticism of the WHO classification
15:35 Coffee break
16:05 PLENARY: Metabolic crosstalk between IGF and insulin systems
16:50 PLENARY: Pituitary tumourigenesis – what's new?
17:25 Day 2 close





3. Agenda - Not To Be Given to Delegates

Saturday 16 th February 2019	
08:30	Welcome to Day 3
SESSION 4	
08:40	PLENARY: Molecular biology for clinicians
09:15	CASE-BASED SYMPOSIUM: Personalised medicine
10:15	Coffee break
SESSION 5	
10:45	Breakout 2
11:45	COUNTRY PERSPECTIVE: Brazil
12:00	Breakout results
12:20	PLENARY: The posterior pituitary shouldn't be forgotten, but how do we assess its function?
12:55	Meeting close

Please note this is a Non promotional meeting





5